Abel Torres-Espin is assistant professor at the School of Public Health Sciences at the University of Waterloo in Canada; adjunct professor at the University of Alberta and assistant adjunct professor at the Brain and Spinal Injury Center in the Weill Institute of Neurosciences at University of California, San Francisco.
Abel Torres-Espin
Assistant adjunct professor
Brain and Spinal Injury Center (BASIC) University of California, San Francisco
From this contributor
By
Adam Ferguson, Hannah Radabaugh, Abel Torres-Espin
4 March 2024
7 min read
Pooling data points to new potential treatment for spinal cord injury
By gathering raw data from multiple labs, we identified an overlooked predictor of recovery after spinal cord injury. Many more insights remain trapped in scattered data.
Explore more from The Transmitter
Measuring plastic in the brain: Improving, but incomplete
Meanwhile, researchers are publishing papers without “sufficient quality control,” says analytical chemist Dušan Materić.
Measuring plastic in the brain: Improving, but incomplete
Meanwhile, researchers are publishing papers without “sufficient quality control,” says analytical chemist Dušan Materić.
By
Amber Dance
18 September 2026 | 9 min read
Incredible shrinking grant deadlines at the BRAIN Initiative
“A month is crazy,” says one former recipient, referring to a new funding opportunity’s timeline.
Incredible shrinking grant deadlines at the BRAIN Initiative
“A month is crazy,” says one former recipient, referring to a new funding opportunity’s timeline.
By
Brendan Borrell
17 September 2026 | 4 min read
Sylvia Fogel, reshaping U.S. autism research strategy
In a wide-ranging and provocative interview, the chair of the federal Interagency Autism Coordinating Committee shares her views on vaccines, regression, neuroimmune conditions and more.
Sylvia Fogel, reshaping U.S. autism research strategy
In a wide-ranging and provocative interview, the chair of the federal Interagency Autism Coordinating Committee shares her views on vaccines, regression, neuroimmune conditions and more.
By
Brady Huggett
17 September 2026 | 2 min read